
Last updated: 2026-09-16 10:31:00. Prices reflect the latest pre-market trading data. Stock price data is sourced from Massive.
Grace Therapeutics, Inc. (GRCE) operates in the PHARMACEUTICAL PREPARATIONS sector and is listed on NASDAQ. The stock is currently priced at $2,24, with a market capitalisation of $48,17M and a P/E ratio of --. Over the past 52 weeks, its price has ranged from $1,79 to $5,18. This page covers its latest market performance, valuation, price trends and company information.
$48,17M | |
$2,29 | |
$5,18 | |
$1,75 | |
$2,29 | |
62,77K | |
218,28K | |
-- | |
$5,18 | |
$1,79 | |
-- | |
-- |
Grace Therapeutics, Inc. (GRCE) is trading at $2,29 in pre-market trading as of 2026-09-15 23:31:00, up 0,17% ($0,00) from the previous close of $2,29
Pre-market trading shows how investors are pricing GRCE before the regular session opens. The current pre-market price is near the previous close, indicating positive early trading sentiment.
Over the past seven days, Grace Therapeutics, Inc. (GRCE) moved from $2,10 to $2,24, representing a gain of 6,57% ($0,14).
The stock traded between $2,05 and $2,46 during the period. The latest price is near the middle of the 7-day range, indicating strong upward.
The average daily volume was 257,07 thousand shares, up versus the previous seven-day period, indicating higher trading activity.
Position in Range: 13,2%
GRCE is currently trading at $2,24, placing it 13,2% of the way from its 52-week low of $1,79 to its 52-week high of $5,18. This percentage reflects the stock's relative position within its 52-week trading range, not its valuation or future performance.
Grace Therapeutics Inc is a late-stage biopharma company with drug candidates addressing rare and orphan diseases. Its development pipeline consists of the following product candidates: GTx-104, a novel injectable formulation of nimodipine for the treatment of a rare disease, aneurysmal subarachnoid hemorrhage (aSAH); GTx-102, targeted for the treatment of ataxia-telangiectasia (A-T) in a pediatric population; and GTx-101, a topical bio adhesive film-forming bupivacaine spray for Postherpetic Neuralgia (PHN), which can be persistent and often causes debilitating pain following infection by the shingles virus. The company has one reportable operating segment: the development and commercialization of pharmaceutical applications of its patents and licensed rights.
| Industry | PHARMACEUTICAL PREPARATIONS |
| Employees | 5 |
| Exchange | NASDAQ |
| Company Website |
Eligible investors can buy real shares of Grace Therapeutics, Inc. (GRCE) through MEXC RealStocks. Follow these three steps to open a RealStocks account, transfer USDT, and place a US stock order.